

**1 Validation of the GE Carescape V100 and Omron HEM-9210T by the**  
**2 AAMI/ESH/ISO 81060-2:2018 in multi-ethnic South-East Asian adult population**

3 Joel Chan<sup>1</sup>, Cai Yue Sophia<sup>1</sup>, Joshua Ng Yong Quan<sup>1</sup>, Syuhaidah Binte Mohammed  
 4 Noor<sup>1</sup>, Shawn Wong Chong Yao<sup>1</sup>, Chan Gerald<sup>1</sup>, Christoph Chong Sheng<sup>1</sup>, Wayne Ng  
 5 Jia Wei<sup>1</sup>, John C. Chambers<sup>1,2</sup>, Marie Loh Chiew Shia<sup>1,2,3</sup>, Theresia H. Mina<sup>1</sup>

6 <sup>1</sup> Nanyang Technological University Lee Kong Chian School of Medicine (NTU  
 7 LKCMedicine), Health Screening Centre, Level 18 Clinical Sciences Building, 11  
 8 Mandalay Road, Singapore 308232

9 <sup>2</sup> Department of Epidemiology and Biostatistics, School of Public Health, Imperial  
 10 College London, 152 Medical School, St Mary's Campus, London, United Kingdom  
 11 W2 1NY

12 <sup>3</sup> National Skin Centre, Department of Research, 1 Mandalay Road, Singapore, 308205  
 13

14 **CORRESPONDING AUTHOR** Theresia H. Mina, Theresia.hm@ntu.edu.sg

15 **CONFLICTS OF INTEREST** None declared.

16

**17 SOURCE OF FUNDING**

18 JCC, MLCS and THM are supported by the intramural funding from NTU  
 19 LKCMedicine, and the National Healthcare Group. JCC is supported by the Singapore  
 20 Ministry of Health's National Medical Research Council under its' STaR funding  
 21 scheme [NMRC/STaR/0028/2017]. THM received postdoctoral fellowship from the  
 22 Singapore Ministry of Education – Research Scholarship Block and NTU  
 23 LKCMedicine.

24 **ABSTRACT**

25 **Objective:** To ascertain the accuracy of 2 upper-arm blood pressure monitors, GE  
26 Carescape V100 Vital Signs and Omron HEM-9210T, used in a large, South-East Asian  
27 epidemiological cohort by the AAMI/ESH/ISO 81060-2:2018.

28 **Methods:** 149 participants were recruited from the ongoing Health for Life in  
29 Singapore (HELIOS) Study in multi-ethnic Singapore.

30 **Results:** 110 datasets were analysed. For criterion 1, the mean  $\pm$  SD of differences for  
31 GE Carescape V100 was  $-3.5 \pm 7.4$  /  $-3.5 \pm 7.4$  mmHg (systolic/diastolic), and  $-4.2 \pm$   
32  $6.9$  /  $-4.2 \pm 6.9$  mmHg (systolic/diastolic) for Omron HEM-9210T. For criterion 2, GE  
33 Carescape V100 was  $-3.5 \pm 5.6$  /  $-3.5 \pm 5.6$  mmHg (systolic/diastolic), and  $-4.2 \pm 4.5$  / -  
34  $4.2 \pm 4.6$  mmHg (systolic/diastolic) for Omron HEM-9210T.

35 **Conclusion:** Both GE Carescape V100 Vital Signs and Omron HEM-9210T monitor  
36 passed the AAMI/ESH/ISO 81060-2:2018 validation standard.

37 **Keywords:** device validation, oscillometric technology, epidemiological study

## 38 INTRODUCTION

39 The limited application of current human genetic studies due to the underrepresentation  
40 of Asians (1), and the urgency to identify etiological risk factors for complex diseases in  
41 Asia are our primary motivations to set the Health for Life in Singapore study  
42 (HELIOS), a prospective longitudinal population cohort comprising the multi-ethnic  
43 Asian adults living in shared environment in Singapore (primary ethnic groups: Chinese  
44 [76%], Malay [15%] and South Asians [9%]). Over the course of HELIOS Study  
45 protocol optimisation and expansion, we have used two upper-arm, automated  
46 sphygmomanometers, the GE Carescape V100 Vital Signs Monitor (referred as “GE”)  
47 and Omron HEM-9210T (referred as “Omron”). Although the Omron device has been  
48 previously validated against the 2013 ANSI/AAMI/ISO (2), no validation study has  
49 been conducted for the GE device. The main aim of this study was to validate both GE  
50 and Omron devices by the AAMI/ESH/ISO 81060-2:2018 standard (3), ensuring the  
51 accuracy and high-quality of the HELIOS research data.

52

## 53 MATERIALS AND METHODS

### 54 Study participants

55 HELIOS is approved by Nanyang Technological University Institutional Review Board  
56 (NTU IRB, reference: IRB-2016-11-030). This validation study was performed as one  
57 of the optional sub-studies offered to participants between August and December 2021.  
58 HELIOS participants were recruited from the general adult population of Singapore,  
59 with the inclusion criteria of being a Singaporean citizen or permanent resident aged 30-  
60 84 years, and the exclusion criteria of being pregnant or breast-feeding, having current  
61 acute illness or recent major surgery or mental incapacities preventing understanding of

62 informed consent. There were 149 participants screened, and 110 participants completed  
63 the validation exercise. We excluded 7 participants due to arrhythmia and 32 due to  
64 blood pressure instability.

## 65 **Device**

66 Both GE (GE Healthcare, Chicago, Illinois, US) and Omron devices (Omron Healthcare  
67 Co. Ltd., Kyoto, Japan) were equipped with a single cuff for arm circumference 23-  
68 33cm and 22-42cm, respectively. The reference manual, mercury-based  
69 sphygmomanometer is Yuwell (Jiangsu Yuyue Medical Equipment & Supply Co. Ltd.),  
70 with single standard cuff with 33cm upper limit, calibrated by the ISO/IEC 17025:2017-  
71 accredited ISOLAB Pte Ltd (Singapore).

## 72 **Procedure**

73 The use of same arm sequential method was adopted (3). A dual-head stethoscope (3M,  
74 Saint Paul, Minnesota, US) was used to facilitate the auscultating and recording of the  
75 reference readings by 2 observers. We fulfilled the requirement for observers,  
76 supervisor and patient preparation as per the standard (3). As HELIOS is an adult  
77 cohort, we did not cover smaller cuff requirements for children and/or subjects aged 12-  
78 29 years. As we validated 2 devices concurrently and to ensure that there is no bias on  
79 the test device sequence, we randomly assigned participants to two arms (The first test  
80 device is Omron followed by GE, or vice versa).

## 81 **Statistical analysis**

82 The data were analyzed as per the standard (3). Bland-Altman plots were created using  
83 SPSS version 26.0 (SPSS, Chicago, USA) according to the standard (3).

84

## 85 RESULTS

86 In this validation study, the mean (SD) age of participants was 52.8 (11.9) years, and the  
87 male proportion was 43 (39.1%). There were 76 (69.1%), 10 (9.1%), 20 (18.2%) and 4  
88 (3.6%) Chinese, Malay, South Asian and other ethnic Asian participants, respectively.  
89 The mean (SD) arm circumference was 25.6 (2.7) cm. **Table 1** describes the distribution  
90 of reference blood pressure measurements. **Table 2** summarizes the mean and SD from  
91 criterion 1 and 2 for the blood pressure difference between the test and reference device.  
92 The Bland-Altman plots do not illustrate any systematic bias (**Fig. 1**).

## 94 DISCUSSION

95 This validation exercise demonstrated that both GE Carescape V100 Vital Signs and  
96 Omron HEM-9210T automated sphygmomanometer used in the HELIOS Study setting  
97 has passed the standard. As compared to the standard requiring 5% of reference systolic  
98 blood pressure measures  $\geq 160$  mmHg, the proportion observed in this validation  
99 exercise was slightly lower, although the diastolic blood pressure fulfilled the  
100 requirement. There could be 2 potential causes; first, most anti-hypertensive  
101 medications are more aggressive in lowering systolic than diastolic blood pressure (4,5),  
102 and second, although we did not observe bias towards healthier participants in the  
103 overall HELIOS Study, such bias could have been greater in this validation exercise as  
104 this exercise was offered as an optional sub-study.

105 In comparison with the earlier Omron validation study using 2013 standard (2),  
106 the mean (SD) difference in this study was also smaller, likely because we only focused  
107 on single-size mid-arm cuff and did not evaluate small or extra-large cuff. In the  
108 HELIOS setting, participants with very severe obesity ( $BMI \leq 40$  Kg/m<sup>2</sup>) and thus more

109 likely to require extra-large cuff remains very rare (data not shown), but if critical  
110 numbers are reached as the study expands, future validation could repeat the exercise  
111 with extra-large cuff.

112

## 113 **CONCLUSION**

114 Both GE Carescape V100 Vital Signs and Omron HEM-9210T automated  
115 sphygmomanometer passed the AAMI/ESH/ISO 81060-2:2018 standard.

## 116 ACKNOWLEDGEMENTS

117 We thank Dr. Terry Tong Yoke Yin, Ms. Shahidah Nur Shifa' Binte Amran, Ms.  
118 Rebekah Wang, Ms. Choo Wee-Lin, and Mr. Lee Hong Kai for logistical and  
119 administrative support. We are grateful to the rest of the HELIOS study operational  
120 team for the overall support during data collection and the Lee Kong Chian School of  
121 Medicine Education Department for loaning the dual-head stethoscope.

122

## 123 REFERENCES

- 124 1. Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature*. 2016;538(7624):161–4.
- 125 2. Alpert BS. Validation of the Omron HEM-9210T by the ANSI/AAMI/ISO 81060-2: 2013 with  
126 two novel cuffs: wide-range and extra-large. *Blood Press Monit*. 2017;22(3):166–8.
- 127 3. Stergiou GS, Palatini P, Asmar R, Ioannidis JP, Kollias A, Lacy P, et al. Recommendations and  
128 Practical Guidance for performing and reporting validation studies according to the Universal  
129 Standard for the validation of blood pressure measuring devices by the Association for the  
130 Advancement of Medical Instrumentation/European Soc. *J Hypertens*. 2019;37(3):459–66.
- 131 4. Heran BS GBP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary  
132 hypertension. *Cochrane Database Syst Rev* [Internet]. 2012;(8). Available from:  
133 <https://doi.org/10.1002/14651858.CD004643.pub3>
- 134 5. Heran BS WMMYHIK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor  
135 blockers for primary hypertension. *Cochrane Database Syst Rev* [Internet]. 2008;(4). Available  
136 from: <https://doi.org/10.1002/14651858.CD003822.pub2>

137

## 138 TABLE AND FIGURE LEGENDS

139 **Table 1. The distribution of reference blood pressure measurements (mmHg)**

140

**Table 1. The distribution of reference blood pressure measurements (mmHg)**

141

	$\leq 100$	$\geq 140$	$\geq 160$
SBP	7.3	96.6	3.4
	$\leq 60$	$\geq 85$	$\geq 100$
DBP	6.6	81.5	18.5

144

145 **Table 2. Mean (SD) for the differences of the device and reference blood pressure values (mmHg).**

146 SBP= systolic blood pressure; DBP= diastolic blood pressure.

147

**Table 2. Mean (SD) for the differences of the device and reference blood pressure values (mmHg).** SBP= systolic blood pressure; DBP= diastolic blood pressure.

Devices	Criterion	SBP	DBP
GE	1	$-3.5 \pm 7.4$	$-3.5 \pm 7.4$
	2	$-3.5 \pm 5.6$	$-3.5 \pm 5.6$
Omron	1	$-4.2 \pm 6.9$	$-4.2 \pm 6.9$
	2	$-4.2 \pm 4.5$	$-4.2 \pm 4.6$

154

155 **Figure 1. Bland-Altman plots of mean device and observer measurements of blood pressure values**

156 **(X-axis) against the device-observer measurements (Y-axis). A) GE, systolic blood pressure (SBP); B)**

157 **Omron, SBP; C) GE, diastolic blood pressure (DBP); D) Omron, DBP.**

158



